Well Jeffery is well known by most here. This is from their press release:
Jeffrey Friedland Joins OWCP's Advisory Board
In March, 2016 we announced that U.S.-based Jeffrey Friedland had joined OWC Pharmaceutical Research's advisory board and would assist as a spokesperson for OWCP in the U.S.
Mr. Friedland is the author of "Marijuana: The World's Most Misunderstood Plant." He is a frequent speaker and panelist at events in the United States and Israel focused on investment opportunities and the cannabis industry. Many of these events provide him with the opportunity to update current OWCP investors and the financial community on OWCP's progress.
Mr. Friedland has been featured or quoted in numerous publications including the Wall Street Journal, Reuters, the New York Times, Bloomberg Television, USA Today, VersloZinios (Lithuania), Vercernji (Croatia), International Business Times, the South China Morning Post, the Guam Daily Post, the Forward, the Jewish Week, Quartz, the Jakarta Globe, Israel Daily Television, BreitBart, NBC.com and Forbes.
He is also the CEO of Intiva Inc., a platform company active in the global cannabis industry in the United States and Canada. In 2014, INTIVA was an initial investor in OWC Pharmaceutical Research.
OWCP's Action Items for 2017:
During the second quarter of 2017 OWCP intends to initiate its U.S marketing program for its Psoriasis Topical Cream. At the same time, we intend to begin investigating the applicability of topical cream for other skin conditions and disorders.
OWCP intends to proceed with the advancement of our cannabis-based treatment for multiple myeloma, with the objective of proceeding with additional studies.
OWCP intends to evaluate the launch of one or more studies to determine the applicability of cannabinoid-based pharmaceuticals for other medical conditions and disorders, such as fibromyalgia and migraines.
News 
Market Data 
Discover 
